Mahmoudian Massoud, Mehrpour Massoud, Benaissa Faouzya, Siadatpour Zahra
Razi Institute for Drug Research, Iran University of Medical Sciences, P.O. Box 14155-6183, Tehran, Iran.
Eur J Clin Pharmacol. 2003 Nov;59(8-9):579-81. doi: 10.1007/s00228-003-0676-1. Epub 2003 Sep 27.
Stroke is the third leading cause of death in most developed countries. Therefore, a need exists for its treatment. Considering the role that is played by bradykinin in pathogenesis of neuronal injury, it has been suggested that bradykinin antagonists may be useful in the treatment of neurological patients. As noscapine can act as an antagonist of bradykinin and can effectively reduce brain injury after hypoxic-ischemic insult in neonatal rats, the present work was carried out to investigate its effectiveness in a clinical setting.
Noscapine was administrated orally to ten acute ischemic stroke patients, and the degree of brain injury was evaluated by computed tomography scan and clinical observation. The control group (n=10) did not receive noscapine treatment.
Our study showed that noscapine effectively improved clinical prognosis and reduced the mortality rate down to 20% compared with 80% in the control group. Our patients did not show any specific side effects due to noscapine.
It is concluded that oral noscapine can be an effective drug for reducing the mortality rate in stroke; however, further study with a larger number of patients is needed to determine its full potential in stroke.
在大多数发达国家，中风是第三大死因。因此，对其治疗存在需求。考虑到缓激肽在神经元损伤发病机制中所起的作用，有人提出缓激肽拮抗剂可能对神经科患者的治疗有用。由于那可丁可作为缓激肽的拮抗剂，并且能有效减轻新生大鼠缺氧缺血性损伤后的脑损伤，因此开展了本研究以调查其在临床环境中的有效性。
对10例急性缺血性中风患者口服那可丁，并通过计算机断层扫描和临床观察评估脑损伤程度。对照组（n = 10）未接受那可丁治疗。
我们的研究表明，与对照组的80%相比，那可丁有效改善了临床预后，并将死亡率降至20%。我们的患者未表现出因那可丁导致的任何特定副作用。
得出结论，口服那可丁可能是降低中风死亡率的有效药物；然而，需要对更多患者进行进一步研究以确定其在中风治疗中的全部潜力。
